PMID- 29180864
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20220317
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 12
DP  - 2017
TI  - A nanoliposome-based photoactivable drug delivery system for enhanced cancer 
      therapy and overcoming treatment resistance.
PG  - 8257-8275
LID - 10.2147/IJN.S143776 [doi]
AB  - Recently, stimuli-responsive drug delivery systems (DDSs) with high 
      spatial/temporal resolution bring many benefits to cancer treatment. However, 
      cancer cells always develop ways to resist and evade treatment, ultimately limit 
      the treatment efficacy of the DDSs. Here, we introduce photo-activated 
      nanoliposomes (PNLs) that impart light-induced cytotoxicity and reversal of drug 
      resistance in synchrony with a photoinitiated and rapid release of antitumor 
      drug. The PNLs consist of a nanoliposome doped with a photosensitizer 
      (hematoporphyrin monomethyl ether [HMME]) in the lipid bilayer and an antitumor 
      drug doxorubicin (DOX) encapsulated inside. PNLs have several distinctive 
      capabilities: 1) carrying high loadings of DOX and HMME and releasing the 
      payloads in a photo-cleavage manner with high spatial/temporal resolution at the 
      site of actions via photocatalysis; 2) reducing drug efflux in MCF-7/multidrug 
      resistance cells via decreasing the level of P-glycoprotein induced by 
      photodynamic therapy (PDT); 3) accumulating in tumor site taking advantage of the 
      enhanced permeability and retention effect; and 4) combining effective 
      chemotherapy and PDT to exert much enhanced anticancer effect and achieving 
      significant tumor regression in a drug-resistant tumor model with little side 
      effects.
FAU - Shi, Jinjin
AU  - Shi J
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou.
AD  - Collaborative Innovation Center of New Drug Research and Safety Evaluation, 
      Zhengzhou, People's Republic of China.
FAU - Su, Yu
AU  - Su Y
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou.
FAU - Liu, Wei
AU  - Liu W
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou.
FAU - Chang, Junbiao
AU  - Chang J
AD  - Collaborative Innovation Center of New Drug Research and Safety Evaluation, 
      Zhengzhou, People's Republic of China.
FAU - Zhang, Zhenzhong
AU  - Zhang Z
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou.
AD  - Collaborative Innovation Center of New Drug Research and Safety Evaluation, 
      Zhengzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20171114
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hematoporphyrins)
RN  - 0 (Lipid Bilayers)
RN  - 0 (Liposomes)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (hematoporphyrin monomethyl ether)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/metabolism
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/pharmacology
MH  - Doxorubicin/administration & dosage/pharmacology
MH  - Drug Delivery Systems/*methods
MH  - Drug Resistance, Multiple/drug effects
MH  - Drug Resistance, Neoplasm/*drug effects
MH  - Female
MH  - Hematoporphyrins/chemistry/pharmacology
MH  - Humans
MH  - Lipid Bilayers/chemistry
MH  - Liposomes/*administration & dosage/chemistry/pharmacology
MH  - MCF-7 Cells
MH  - Mice, Inbred BALB C
MH  - Nanostructures/administration & dosage/chemistry
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5694201
OTO - NOTNLM
OT  - drug delivery
OT  - multidrug resistance
OT  - photo-responsive release
OT  - photocatalysis
OT  - photodynamic-chemotherapy
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/11/29 06:00
MHDA- 2018/03/06 06:00
PMCR- 2017/11/14
CRDT- 2017/11/29 06:00
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2017/11/14 00:00 [pmc-release]
AID - ijn-12-8257 [pii]
AID - 10.2147/IJN.S143776 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2017 Nov 14;12:8257-8275. doi: 10.2147/IJN.S143776. 
      eCollection 2017.